CMEO Webcast

Premiere Date: Monday, November 19, 2018

This activity offers CE credit for:

Physicians (CME)

ABIM

Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Monday, November 18, 2019

Faculty

Christopher P. Cannon, MD (Moderator)Director, Education, Cardiovascular Medicine InnovationCardiovascular Division, Brigham and Women?s HospitalProfessor of Medicine, Harvard Medical SchoolBoston, MA

Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s Hospital Heart & Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, MA

Elaine M. Hylek, MD, MPH Director, Thrombosis and Anticoagulation ServiceBoston Medical CenterProfessor of MedicineBoston University School of MedicineBoston, MA

Statement of Need

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and a leading cause of morbidity and mortality. Due to the increasing age of the U.S. population, the “perceived” incidence of AF is increasing; however, patients may not notice symptoms that warrant care-seeking. This leads to physicians not having an index of suspicion relative to those at high risk for AF. Increased screening and use of anticoagulation treatment can help high-risk patients and likely decrease the number of patients who are not diagnosed with AF until they have had an AF-related stroke. 

In this CME Outfitters On Demand, expert faculty address the impact of underdiagnosed NVAF and the benefits and uses of screening tools and appropriate implementation of oral anticoagulant therapy.

Learning Objectives

At the end of this CE activity, participants should be able to:

Examine the significance of identifying patients at high risk for NVAF in the primary care setting who might benefit from anticoagulant therapy.

Financial Support

Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Target Audience

Primary care physicians, cardiologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with non-vascular atrial fibrillation.

Credit Information

CME Credit (Physicians):CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse Practitioners can also apply for credit through their state boards. 

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. 

ABIM/MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Learning Formats Endurin

To Receive Credit post-tests, credit request forms, and activity evaluations must be completed online at https://cmeo.mycrowdwisdom.com/diweb/catalog/item?id=2414036 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required).

To Receive Credit post-tests, credit request forms, and activity evaluations must be completed online at https://cmeo.mycrowdwisdom.com/diweb/catalog/item?id=3336943 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required).

To Receive Credit post-tests, credit request forms, and activity evaluations must be completed online at https://cmeo.mycrowdwisdom.com/diweb/catalog/item?id=3336928 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required).

CMEO Live and On Demand

Premiere Date: Thursday, July 12, 2018

This activity offers CE credit for:

Physicians (CME)

Nurses (CNE)

Pharmacists (ACPE)

ABIM (ABIM)

Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, July 12, 2019

Begin Activity Now

Faculty

 

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Professor of Medicine, Healthcare Policy and Research

Weill Medical College of Cornell University

Attending Rheumatologist

Hospital for Special Surgery

New York, NY

 

Joel M. Gelfand, MD, MSCE

Professor of Dermatology

Professor of Epidemiology

Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit

Director, Psoriasis and Phototherapy Treatment Center

University of Pennsylvania Perelman School of Medicine

Philadelphia, PA

 

Jennifer G. Kwan-Morley, MD

Rheumatologist

Premier Orthopaedics

Malvern, PA

Co-provided by

 

Statement of Need

Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes.

In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.

Learning Objectives

At the end of this CE activity, participants should be able to:

Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.

Develop individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.

Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

The following learning objectives pertain only to those requesting CNE or CPE credit:

Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.

Describe individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.

Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

Financial Support

Supported by educational grants from Celgene Corporation; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; and Novartis Pharmaceuticals Corporation

Target Audience

Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis

Credit Information

CME Credit (Physicians):

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with their participation in this activity.

CNE Credit (Nurses):

Provider approved by the California Board of Registered Nursing, P

To Receive Credit post-tests, credit request forms, and activity evaluations must be completed online at https://cmeo.mycrowdwisdom.com/diweb/catalog/item?id=2478171 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required).

CMEO Medical Meeting

Symposium Date: Monday, June 4, 2018

On June 4, 2018, Sheraton Hotel, Seattle, WA

This activity offers CE credit for:

Physicians (CME)

Nurses (CNE)

Pharmacists (ACPE)

ABIM (ABIM)

Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, June 4, 2019

Begin Activity Now

Faculty

 

Flavio Vincenti, MD

Professor of Clinical Medicine and Surgery

Medical Director, Kidney-Pancreas Program

University of California San Francisco

San Francisco, CA

 

Dorry  Segev, MD, PhD

Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology

Associate Vice Chair, Department of Surgery

Director, Epidemiology Research Group in Organ Transplantation

Johns Hopkins University

Baltimore, MD

 

Statement of Need

The optimization of immunosuppression is an important modifiable risk factor that can have a positive impact on long-term outcomes in transplantation. Breakthroughs in transplant procedures and the development of more effective immunosuppressive therapies have improved patient outcomes, with short-term survival rates over 80%. However, by five years post-transplant, up to 25% of patients have returned to dialysis, and 50% of all grafts fail within 10 years. Emerging literature that supports minimization or elimination of CNI therapy while maintaining optimal levels of immunosuppression, may offer new strategies for post-transplant immunosuppression.

Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025. Join experts Dr. Vincenti and Dr. Segev as they translate the dynamics of immunosuppression optimization, precision medicine, and the impact of big data on the future of transplant medicine.

Learning Objectives

At the end of this CE activity, participants should be able to:

Identify modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.

Integrate strategies to optimize immunosuppression and minimize adverse events in transplant recipients.

Explore the impact of big data on precision medicine and the future of transplant medicine.

The following learning objectives pertain only to those requesting CNE or CPE credit:

Differentiate between modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.

Assess strategies to optimize immunosuppression and minimize adverse events in transplant recipients.

Analyze the impact of big data on precision medicine and the future of transplant medicine.

Financial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Transplant surgeons, nephrologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat transplant patients.

Credit Information

CME Credit (Physicians):

CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):

Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Contin